Neurocrine Biosciences Inc Reports 29 percent YoY Growth in Q3 2023 Net Product Sales - Yahoo Finance
| N1BI34 Stock | 37.51 0.52 1.41% |
About 52% of Neurocrine Biosciences' investors are presently thinking to get in. The analysis of current outlook of investing in Neurocrine Biosciences suggests that some traders are interested regarding Neurocrine Biosciences' prospects. The current market sentiment, together with Neurocrine Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Neurocrine Biosciences stock news signals to limit their universe of possible portfolio assets.
Neurocrine |
Neurocrine Biosciences Inc Reports 29 percent YoY Growth in Q3 2023 Net Product Sales Yahoo Finance
Read at news.google.com
 |
Neurocrine Biosciences Fundamental Analysis
We analyze Neurocrine Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurocrine Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurocrine Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Neurocrine Biosciences is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Neurocrine Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neurocrine Biosciences stock to make a market-neutral strategy. Peer analysis of Neurocrine Biosciences could also be used in its relative valuation, which is a method of valuing Neurocrine Biosciences by comparing valuation metrics with similar companies.
Peers
Neurocrine Biosciences Related Equities
| T1MU34 | T Mobile | 3.24 | ||||
| U2ST34 | Unity Software | 2.72 | ||||
| CHCM34 | Charter Communications | 2.22 | ||||
| VERZ34 | Verizon Communications | 1.32 | ||||
| GPIV33 | GP Investments | 1.27 | ||||
| CTSH34 | Cognizant Technology | 0.00 | ||||
| A1IV34 | Apartment Investment | 0.23 |
Complementary Tools for Neurocrine Stock analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |